XML 78 R64.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Note 15 - Revenue by Product Group, by Significant Customer and by Geographic Region; Geographic Information - Product Revenue by Product Group (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Product Revenue | $ 28,884 | $ 27,178 | $ 28,340 | $ 23,381 | $ 28,296 | $ 25,783 | $ 26,575 | $ 22,278 | $ 107,783 | $ 102,932 | $ 87,696
Concentration risk, percentage |  |  |  |  |  |  |  |  | 100.00% | 100.00% | 100.00%
Orthobiologics [Member] |  |  |  |  |  |  |  |  |  |  |
Product Revenue |  |  |  |  |  |  |  |  | $ 93,816 | $ 89,695 | $ 73,247
Concentration risk, percentage |  |  |  |  |  |  |  |  | 87.00% | 87.00% | 84.00%
Dermal [Member] |  |  |  |  |  |  |  |  |  |  |
Product Revenue |  |  |  |  |  |  |  |  | $ 2,755 | $ 2,759 | $ 2,266
Concentration risk, percentage |  |  |  |  |  |  |  |  | 3.00% | 3.00% | 2.00%
Surgical [Member] |  |  |  |  |  |  |  |  |  |  |
Product Revenue |  |  |  |  |  |  |  |  | $ 5,262 | $ 5,427 | $ 5,812
Concentration risk, percentage |  |  |  |  |  |  |  |  | 5.00% | 5.00% | 7.00%
Other [Member] |  |  |  |  |  |  |  |  |  |  |
Product Revenue |  |  |  |  |  |  |  |  | $ 5,950 | $ 5,051 | $ 6,371
Concentration risk, percentage |  |  |  |  |  |  |  |  | 5.00% | 5.00% | 7.00%

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductOrServiceAxis=anik_OrthobiologicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=anik_DermalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=anik_SurgicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=anik_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |